Vedolizumab: An integrin-receptor antagonist for treatment of Crohn’s disease and ulcerative colitis
| Autor: | Ashton E. Beggs, Kristy Wahaib, Leela Kodali, Vanessa Kirkwood, Lindsay Hahn |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Integrins
medicine.medical_specialty Nausea Antibodies Monoclonal Humanized Gastroenterology Vedolizumab Crohn Disease Maintenance therapy Internal medicine medicine Humans Infusions Intravenous Adverse effect Pharmacology Crohn's disease business.industry Health Policy medicine.disease Ulcerative colitis Rash Surgery Upper respiratory tract infection Clinical Trials Phase III as Topic Colitis Ulcerative medicine.symptom business medicine.drug |
| Zdroj: | American Journal of Health-System Pharmacy. 72:1271-1278 |
| ISSN: | 1535-2900 1079-2082 |
| DOI: | 10.2146/ajhp140449 |
| Popis: | Purpose The pharmacology, pharmacokinetics, safety, efficacy, and dosing recommendations of vedolizumab, an integrin-receptor antagonist for the treatment of Crohn’s disease (CD) and ulcerative colitis (UC), are reviewed. Summary Vedolizumab is an integrin-receptor antagonist for the treatment of CD and UC in adults with moderately to severely active disease who have had an inadequate response with, lost response to, or were intolerant to anti-tumor necrosis factor (TNF) agents or immunomodulators or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids. Phase III clinical trials have demonstrated efficacy in achieving remission as induction and maintenance therapy in CD and UC. Remission was also achieved at week 10 in patients with CD in whom previous treatment with anti-TNF agents had failed. Adverse effects of vedolizumab include nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, and pain in the extremities. To date, no cases of progressive multifocal leukoencephalopathy (PML) have been reported. The recommended dose of vedolizumab in adults with UC or CD is 300 mg administered via intravenous infusion at zero, two, and six weeks, followed by every eight weeks. The average wholesale unit price is $5782.80, but a patient assistance program is available. Conclusion Vedolizumab is a new alternative for patients with moderate-to-severe UC or CD, as well as patients who have not responded to anti-TNF agents. The current safety profile and lack of reported PML make it a promising addition to the treatment of these conditions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|